NACFC 2022

With continual advances in treatment, more people with cystic fibrosis (CF) are surviving well into adulthood and by 2040, nearly three-quarters of these patients in the U.S. will be adults. That’s according to a study, “…

Women and girls with cystic fibrosis (CF) who are being treated with antibiotics due to a pulmonary exacerbation tend to have better lung function compared with male patients, but report more severe symptoms, new data show. Kristina Montemayor,…

CFTR modulators, a highly effective therapy for cystic fibrosis (CF), do not appear to affect fertility outcomes for men using them, data from surveys of these patients indicate. Miscarriages during pregnancy for a woman whose partner is using modulator therapy and…

Note: This story was updated Nov. 9 to note that experiments done with Sionna’s CFTR modulators used a different investigational NBD1 stabilizer than SION-638. SION-638, a first-in-class small molecule that is being developed by Sionna Therapeutics, improved the…

Exposure to tobacco smoke may reduce the effectiveness of Kalydeco (ivacaftor), a CFTR modulator that is widely approved to treat cystic fibrosis (CF) caused by specific mutations. That’s according to data shared by Gabriela Oates, PhD, at…

A novel scoring system may be used to classify the severity of lung disease among children with cystic fibrosis (CF) in their first years of life. Leslie Huang, a medical student at the University of Wisconsin, discussed the…

Treatment with Trikafta continues to be safe and well-tolerated, benefiting people with cystic fibrosis (CF) ages 12 and up who have been on treatment for almost three years. But benefits may also extend to children as young…